Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug

28 Jun 2024

Abstract excerpt

Abstract SARS-CoV-2 infection is initiated by Spike glycoprotein binding to the human angiotensin-converting enzyme 2 (ACE2) receptor via its receptor binding domain. Blocking this interaction has been proven to be an effective approach to inhibit virus infection. Here we report the discovery of a neutralizing nanobody named VHH60, which was directly produced from an engineering nanobody library based on a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38937437
DOI: 10.1038/s41419-024-06802-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drugPMID 38937437Read ↗

Broad neutralizing nanobody against SARS-CoV-2 engineered from pre-designed synthetic librarySemantic proximity Read ↗

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variantsSemantic proximity Read ↗

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read ↗

Peptide derived nanobody inhibits entry of SARS-CoV-2 variantsSemantic proximity Read ↗

A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potentialSemantic proximity Read ↗

High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting EnzymeSemantic proximity Read ↗

A bivalent spike-targeting nanobody with anti-sarbecovirus activitySemantic proximity Read ↗

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2Semantic proximity Read ↗

Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing NanobodiesSemantic proximity Read ↗

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2Semantic proximity Read ↗

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesSemantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.